• Reported GAAP EPS of -$0.20 up 20.00% YoY • Reported revenue of $0.65M down -2.26% YoY • Absci expects interim proof-of-concept data for ABS-201 in androgenetic alopecia in the second half of 2026, and plans to initiate a Phase 2 clinical trial for ABS-201 in endometriosis in Q4 2026.
Bullish
Absci utilizes its AI-native platform for capital-efficient drug development, focusing on unmet medical needs. Early ABS-201 clinical data shows a favorable safety profile, with preclinical studies indicating significant hair regrowth.
Bearish
Absci faces increasing net losses and R&D expenses, requiring more capital. Biologic drug development is uncertain and competitive, with regulatory changes and AI technology risks potentially delaying programs.